Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.
Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.
Avanos Medical (NYSE: AVNS) has been acquired by affiliates of investment funds advised by American Industrial Partners (AIP) in a transaction valued at approximately $1.272 billion. Under the merger agreement, Avanos stockholders will receive $25.00 in cash per share of common stock they own.
Following the closing, Avanos common stock will cease trading on the New York Stock Exchange and the company will become privately held. According to AIP and Avanos, the partnership is intended to support Avanos’ growth and innovation roadmap in the medical technology sector. Legal, financing and financial advisors to both parties included Sidley Austin, Ropes & Gray, Baker Botts, J.P. Morgan Securities, UBS Investment Bank and Alston & Bird.
Avanos Medical (NYSE: AVNS) announced that stockholders approved the pending acquisition of Avanos by affiliates of funds advised by American Industrial Partners (AIP) at a July 22, 2026 special meeting. Based on preliminary results, approximately 99.75% of shares voted supported the deal, representing about 74.96% of total outstanding common shares as of the June 18, 2026 record date.
Under the merger agreement, Avanos stockholders will have the right to receive $25.00 in cash per share at the effective time of the acquisition. Avanos stated that all required regulatory approvals under the merger agreement have been received and that the transaction is expected to close no later than July 27, 2026, subject to customary closing conditions. Final voting results will be detailed in a Form 8-K filing with the U.S. Securities and Exchange Commission.
S&P Dow Jones Indices announced changes to the S&P MidCap 400 and S&P SmallCap 600 effective before trading on July 24 and July 27, 2026. On July 24, Krystal Biotech (KRYS) will move from the S&P SmallCap 600 to join the S&P MidCap 400, replacing Taylor Morrison Home (TMHC). Tutor Perini (TPC) will be added to the S&P SmallCap 600, replacing Krystal Biotech.
According to S&P Dow Jones Indices, Berkshire Hathaway (BRK.A/BRK.B) is acquiring Taylor Morrison Home, with closing expected on or about July 24, pending final conditions. On July 27, V2X (VVX) will join the S&P SmallCap 600, replacing Avanos Medical (AVNS), which is being acquired by American Industrial Partners, also pending final closing conditions.
Avanos Medical (NYSE: AVNS) and American Industrial Partners announced receipt of all required regulatory approvals for the pending acquisition of Avanos by AIP-advised funds. The merger is expected to close by July 27, 2026, pending Avanos stockholder approval and other customary closing conditions.
The special stockholder meeting to vote on the transaction is scheduled for July 22, 2026 at 9:00 a.m. ET in Atlanta.
Avanos (NYSE: AVNS) reported Q1 2026 results and agreed to be acquired by affiliates of American Industrial Partners for an enterprise value of $1.272 billion. Q1 net sales were $182.2 million (up 8.8%). Specialty Nutrition Systems sales rose by $22.9 million to $124.0 million. GAAP net income was $5.1 million; adjusted net income was $10.6 million. Cash used in operations was an outflow of $12.3 million, and total debt was $98.2 million as of March 31, 2026.
Avanos (NYSE: AVNS) agreed to be acquired by affiliates of American Industrial Partners for an enterprise value of approximately $1.272 billion. Avanos stockholders will receive $25.00 per share in cash, a ~72.1% premium to the April 13, 2026 close and an ~82.8% premium to the 30-day VWAP.
The transaction, unanimously approved by the Avanos board, is expected to close in the second half of 2026, is not subject to a financing condition, and will result in Avanos becoming a private company.
Avanos Medical (NYSE: AVNS) will present at the 2026 Citizens Life Sciences Conference on March 11, 2026. CEO Dave Pacitti and CFO Scott Galovan will appear in a fireside chat at ~1:05 p.m. ET.
A live webcast will be available and later archived on the company's Investors webpage.
Avanos Medical (NYSE: AVNS) announced it will nominate James L. Cunniff and William P. Burke as independent directors for election at the Company’s 2026 Annual Meeting, subject to customary background checks.
Avanos entered into a cooperation agreement with Bradley L. Radoff in connection with the nominations; the agreement will be filed as an exhibit to a Current Report on Form 8-K. The Company will include its formal board recommendation in its definitive proxy materials to be filed with the SEC. The 2026 meeting date is not yet scheduled.
Avanos Medical (NYSE: AVNS) reported fourth-quarter and full-year 2025 results on Feb 24, 2026, with full-year net sales of $701.2M and adjusted diluted EPS of $0.94. The company delivered organic growth in strategic segments, recorded a $77.0M goodwill impairment, and expects $15–20M of incremental annualized savings by end of 2026.
Q4 net sales were $180.9M, adjusted EBITDA for the year was $86.8M, year-end cash totaled $89.8M, and net debt was $10.7M.
Avanos Medical (NYSE: AVNS) will webcast a conference call to discuss fourth quarter and full year 2025 financial results on Feb. 24, 2026 at 9:00 a.m. ET. A news release with results will be issued before market open that day.
The call will be hosted by CEO Dave Pacitti and SVP/CFO Scott Galovan. Investors can join by phone, register for instant dial-in, or listen to a simultaneous webcast via the Avanos investors website. A replay will be available about two hours after the call and remain accessible for one week.